Info

🌱 來自: Antibody Drug Conjugates

Moxetumomab pasudotox

• Mechanism: CD22-directed antibody-drug fused to Pseudomonas exotoxin (PE38) which is internalized & causes inhibition of protein synthesis & apoptotic cell death
• Approved indication: Hairy cell leukemia
• Dosing: 0.04 mg/kg on d 1, 3, 5 of 28-d cycle administered w/ 1 L isotonic IV before & after + H1 & H2 antagonists before + oral corticosteroid after infusion; consider low-dose aspirin on d 1-8 of each cycle; delay infusion for ≥grade 2-3 SCr; grade 2 capillary leak syndrome delay tx, grade 3-4 discontinue; discontinue for hemolytic uremic syndrome
• PK/PD: T1/2 1.4 h
• AEs: Capillary leak syndrome, infusion rxns, hemolytic uremic syndrome, ↓ albumin, ↓ Ca, ↓ Phos, ↑ LFTs
• DDI: N/A